Table 2.
Univariable analysis of ALN pCR in the retrospective patient series.
| Variable | OR | 95% CI | P value |
| Age∗ | 0.39 | 0.203–1.996 | 0.867 |
| Pathological type | |||
| IDC | 1 | ||
| Others† | 1.184 | 0.105–13.33 | 0.891 |
| Clinical T stage | |||
| T1 | 1 | ||
| T2 | 0.449 | 0.180–1.119 | 0.085 |
| T3 | 0.552 | 0.220–1.384 | 0.205 |
| T4 | 0.321 | 0.120–0.854 | 0.023 |
| Primary tumor response | |||
| PR and SD | 1 | ||
| CR | 1.082 | 1.011–1.158 | 0.023 |
| Histological grade | |||
| I | 1 | ||
| II | 1.216 | 0.704–1.747 | 0.801 |
| III | 1.585 | 0.523–2.027 | 0.665 |
| ER | |||
| Negative | 1 | ||
| Positive | 0.554 | 0.287–0.807 | <0.001 |
| PR | |||
| Negative | 1 | ||
| Positive | 0.568 | 0.296–0.890 | 0.039 |
| HER2 | |||
| Negative | 1 | ||
| Positive | 1.215 | 0.649–2.410 | 0.052 |
∗
Continuous variables.
†
Others, invasive lobular carcinoma, invasive papillary carcinoma, mucinous carcinoma. ALN: Axillary lymph node; CR: Complete response; CI: Confidence interval; ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; IDC: Invasive ductal carcinoma; Clinical T stage: Clinical tumor stage; OR: Odds ratio; PR: Partial response; PR: Progesterone receptor; pCR: Pathological complete response; SD: Stable disease.